Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsLaurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurelien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, Francois-Xavier Danlos3 May 2024
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapyBao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, Ying Wu, Yan Ling, Yuan-Sheng Zang16 April 2024
Do galectins serve as soluble ligands for immune checkpoint receptors?Nicolas I Torres, Federico G Baudou, Marco A Scheidegger, Tomás Dalotto-Moreno, Gabriel A Rabinovich9 April 2024
Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancerXueli Xia, Kai Yin, Shengjun Wang4 April 2024
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trialsMichael T Lotze, Tricia Cottrell, Carlo Bifulco, Laura Chow, Leslie Cope, Sacha Gnjatic, Holden T Maecker, Joe Yeong Poh Shen21 March 2024
Suppressive effects of obesity on NK cells: is it time to incorporate obesity as a clinical variable for NK cell-based cancer immunotherapy regimens?Robert J Canter, Sean J Judge, Craig P Collins, Daniel Jaeho Yoon, William J Murphy13 March 2024
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufactureJ Joseph Melenhorst, Beatriz C Oliveira13 March 2024
Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panelAmanda A Myers, Ashish M Kamat, Angela Kilbert, Matthew D Galsky2 February 2024
CARs are sharpening their weaponsAlice Pievani, Marta Biondi, Sarah Tettamanti, Andrea Biondi, Gianpietro Dotti, Marta Serafini31 January 2024